Multivariate Cox regression model estimates
| Variable . | Comparisons . | OS . | PFS . | ||
|---|---|---|---|---|---|
| HR (CI 95%) . | Wald P value . | HR (CI 95%) . | Wald P value . | ||
| Cohort | BBB vs ibrutinib | 6.81 (2.18-21.25) | <.001 | 4.62 (1.72-12.45) | .002 |
| Additional IT chemotherapy | No vs yes | 1.29 (0.61-2.73) | .502 | 1.43 (0.73-2.82) | .301 |
| Morphology variant | Blastoid vs classic | 1.69 (0.73-3.92) | .118 | 1.50 (0.68-3.29) | .265 |
| Pleomorphic vs classic | 3.25 (1.02-10.36) | 2.26 (0.79-6.48) | |||
| CNS-POD ≤24 mo | Yes vs no | 2.41 (1.11-5.25) | .026 | 2.27 (1.12-4.61) | .023 |
| Variable . | Comparisons . | OS . | PFS . | ||
|---|---|---|---|---|---|
| HR (CI 95%) . | Wald P value . | HR (CI 95%) . | Wald P value . | ||
| Cohort | BBB vs ibrutinib | 6.81 (2.18-21.25) | <.001 | 4.62 (1.72-12.45) | .002 |
| Additional IT chemotherapy | No vs yes | 1.29 (0.61-2.73) | .502 | 1.43 (0.73-2.82) | .301 |
| Morphology variant | Blastoid vs classic | 1.69 (0.73-3.92) | .118 | 1.50 (0.68-3.29) | .265 |
| Pleomorphic vs classic | 3.25 (1.02-10.36) | 2.26 (0.79-6.48) | |||
| CNS-POD ≤24 mo | Yes vs no | 2.41 (1.11-5.25) | .026 | 2.27 (1.12-4.61) | .023 |